M.D.C.T. Benelux SA
Dissolution judiciaire ou nullitéM.D.C.T. Benelux reported total assets of 184,719 € at the end of the 2025 financial year (annual accounts filed with the NBB on 27 Oct 2026).
The score of M.D.C.T. Benelux shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets +16 %
Accounts of the company itself (not consolidated).
The full file covers 15 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
M.D.C.T. Benelux's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 27 Oct 2026
- Year ended 31 Dec 2024filed on 19 Dec 2025
- Year ended 31 Dec 2023filed on 02 Sep 2025
- Year ended 31 Dec 2022filed on 02 Sep 2025
- Year ended 31 Dec 2021filed on 02 Sep 2025
M.D.C.T. Benelux's financial analysis
- Solvency-72.7%sector median: 56.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of M.D.C.T. Benelux
M.D.C.T. Benelux's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0464.081.850
- VAT number
- BE0464081850
- Peppol
- Not found on Peppol as of 10 Nov 2026 · Check
- Legal form
- SA
- Incorporated
- 03 Sep 1998
- Registered office
- 9800 Deinze
- Latest accounts
- 2025 · filed on 27 Oct 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
M.D.C.T. Benelux (SA) has been based in Deinze since 1998, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net loss of 51,489 € and equity of −134,382 €; its revenue is not published. Its solvency stands at -72.7%, below the median of its sector (56.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to M.D.C.T. Benelux
Companies in the same business, of comparable size and area, outside its group.
- Montefalcone Projects Manufacture of basic pharmaceutical products Maarkedal · balance sheet 207,746 €
- huMAN Manufacture of basic pharmaceutical products Gerpinnes · balance sheet 186,227 €
- Abella Mar Manufacture of basic pharmaceutical products Kapellen · balance sheet 150,376 €
- Promacon Manufacture of basic pharmaceutical products Hove · balance sheet 408,759 €
- Yaro Preclinical Consulting Manufacture of basic pharmaceutical products Turnhout · balance sheet 158,481 €
- Asclepia MedChem Solutions Manufacture of basic pharmaceutical products Destelbergen · balance sheet 360,741 €
- Make IT Work Consulting Manufacture of basic pharmaceutical products Hamois · balance sheet 220,980 €
- Medipharm Worldwide Group Manufacture of basic pharmaceutical products Tienen · balance sheet 331,081 €
Frequently asked questions about M.D.C.T. Benelux
What is the revenue of M.D.C.T. Benelux?
M.D.C.T. Benelux files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of M.D.C.T. Benelux?
In Belgium, the VAT number is the company number prefixed with BE: BE0464081850 for M.D.C.T. Benelux, if the company is VAT-registered. Its company number (CBE) is 0464.081.850.
Where is the registered office of M.D.C.T. Benelux?
According to the CBE register, the registered office of M.D.C.T. Benelux is in 9800 Deinze.
What is the equity of M.D.C.T. Benelux?
At the close of the 2025 financial year, the equity of M.D.C.T. Benelux amounts to -134,382 €, a solvency of -72.7% of total assets.
Who manages M.D.C.T. Benelux?
The register lists 4 active mandates at M.D.C.T. Benelux. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of M.D.C.T. Benelux
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →